Safety and efficacy of phacoemulsification in dealing with complicated uveitic cataracts
Session Details
Session Title: Presented Poster Session: Cataract Complications & Special Cases
Venue: Poster Village: Pod 1
First Author: : M.Mahendra INDIA
Co Author(s): : S. Mahendra
Abstract Details
Purpose:
To asses and evaluate the safety and efficacy of phacoemulsification in various types of complicated uveitic cataracts.
Setting:
Khairabad Eye Hospital,Kanpur,India
Methods:
A total of 156 eyes of 121 patients with complicated uveitic cataracts were operated between 1st January 2012 to 1st January 2017 Routine phacoemulsification was performed with Alcon infinity phaco machine using ozil technology and direct phacochop technique through a 2.2mm clear corneal temporal incision.The study included various types of post uveitic cataracts namely occlusio pupillae,non dilating miotic pupil,festooned pupil,post trabeculectomy uveitic cataract and mature hard white uveitic cataracts. Standard preoperative regimen of topical as well as systemic steroids were instituted a week before surgical intervention. All cases were performed by a single surgeon using small pupil management devices.
Results:
Intraoperative complications were negligible with few incidents of anterior chamber instability (4.49%) , descemets stripping (2.57%),floppy iris (23.08%) ,uncontrolled rhexis formation (3.85%) and linear mark imprints at the pupillary margin due to iris retractors(28.21%). Post operative complications included day 1 postoperative corneal oedema (20.51%), fibrinous reaction(13.46%),increased intraocular pressure (8.97%) ,cystoid macular oedema (12.18%),pupillary capture (2.56%),posterior capsular opacification (18.59%).More complications were observed in hard uveitic cataracts.A high percentage of (82.05%) recorded a best corrected visual acuity of 6/12 or better.
Conclusions:
Adequate exposure of pupillary area using pupil expanding devices and malyugin ring makes phacoemulsification safe and effective in these cases and helps overcome unavoidable complications.
Financial Disclosure:
None